News

The Mauli Ola Foundation’s (MOF) 2014 national Ohana Tour will finish on the North Shore of Oahu, and the event will include pediatric visits and Surf Experience Days to help those suffering with cystic fibrosis. Jamie O’Brien, the pipeline master, will be hosting the final 2014 Surf Experience which…

One of the ways the Cystic Fibrosis Trust is celebrating its 50th Anniversary this year is through a month-long Thank You campaign, meant to cap off the year on a high note, and with a surge of hope. The UK not-for-profit organization created a…

Thanks to a fundraising initiative organized by the staff members of the University Hospital of South Manchester NHS Foundation Trust (UHSM), patients at the facility who suffer from cystic fibrosis (CF) now have the possibility of improving their symptoms using state-of-the-art exercise equipment, with two new, modern exercise bikes…

A new Cystic Fibrosis study entitled “Early Respiratory Infection Is Associated with Reduced Spirometry in Children with Cystic Fibrosis” was published in American Journal of Respiratory and Critical Care Medicine by Dr. Kathryn A. Ramsey, part of Graham L. Hall’s group from the Telethon Kids…

Drug developer Proteostasis Therapeutics, Inc., which is currently studying protein homeostasis regulation as a treatment for orphan and neurodegenerative diseases such as cystic fibrosis (CF), recently named Po-Shun Lee, MD as their new vice-president of clinical development. The pulmonary and critical care physician, who has been responsible for leading research programs on…

Virginia-based surgical and medical instrument manufacturer PulmoFlow, Inc. announced Tuesday, December 2 that the US Food and Drug Administration has granted final approval of its New Drug Application for the Kitabis Pak. The drug is a co-packaging of tobramycin inhalation solution and the PARI LC PLUS® Reusable Nebulizer, which is the first…

A new study published in the Orphanet Journal of Rare Diseases, presented the effectiveness of Cysteamine for the treatment of Cystic Fibrosis. The study, entitled  “Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis” was conducted by NovaBiotics Ltd.  researchers. Cystic…

Two recently published reviews in peer-reviewed journals plus another study highlight the potential utility of ceragenins or cationic selective antimicrobials (CSAs) — a proprietary, patented, first-in-class small molecule technology platform for fighting bacterial infections, such as pulmonary infections associated with cystic fibrosis (CF) and hospital acquired infections associated with…

Researchers in the Netherlands found that although adolescents with cystic fibrosis had a higher breathing response to exercise, they were able to breathe adequately enough to be able to perform a moderate exercise task. Cystic fibrosis is one of the most commonly occurring chronic diseases of the lungs…

Corbus Pharmaceuticals has been invited to present during this Thursday’s VirtualInvestorConferences.com on its lead pipeline product Resunab™, indicated for the treatment of serious inflammatory and fibrotic diseases, namely cystic fibrosis and diffuse scleroderma. Representing the company during the upcoming online, live event is CEO Yuval Cohen,…